Biomedical Research Bill Approved in House

The 21st Century Cures Act could provide funds to federal research agencies for the decade and accelerate the drug approval process.

| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

FLICKR, ADNAN ISLAM

The House of Representatives passed legislation intended to fast-track biomedical research by a 392 to 26 vote, STAT News reported. The 21st Century Cures Act is a sweeping bill that would allocate funds to the National Institutes of Health (NIH) and streamline drug approval regulation by the Food and Drug Administration (FDA).

The bill, which will now be sent to the Senate for approval, includes $4.8 billion dollars in funding for three NIH programs: the Precision Medicine Initiative, the Cancer Moonshot, and the BRAIN Initiative, according to Science. The bill may also loosen certain FDA regulations, allowing a drug approved for treating one disease to be applied to a related disease without restarting the entire process, according to NPR.

The legislation is not without controversy, ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Keywords

Meet the Author

  • Ben Andrew Henry

    This person does not yet have a bio.
Share
TS Digest January 2025
January 2025, Issue 1

Why Do Some People Get Drunk Faster Than Others?

Genetics and tolerance shake up how alcohol affects each person, creating a unique cocktail of experiences.

View this Issue
Sex Differences in Neurological Research

Sex Differences in Neurological Research

bit.bio logo
New Frontiers in Vaccine Development

New Frontiers in Vaccine Development

Sino
New Approaches for Decoding Cancer at the Single-Cell Level

New Approaches for Decoding Cancer at the Single-Cell Level

Biotium logo
Learn How 3D Cell Cultures Advance Tissue Regeneration

Organoids as a Tool for Tissue Regeneration Research 

Acro 

Products

Artificial Inc. Logo

Artificial Inc. proof-of-concept data demonstrates platform capabilities with NVIDIA’s BioNeMo

Sapient Logo

Sapient Partners with Alamar Biosciences to Extend Targeted Proteomics Services Using NULISA™ Assays for Cytokines, Chemokines, and Inflammatory Mediators

Bio-Rad Logo

Bio-Rad Extends Range of Vericheck ddPCR Empty-Full Capsid Kits to Optimize AAV Vector Characterization

Scientist holding a blood sample tube labeled Mycoplasma test in front of many other tubes containing patient samples

Accelerating Mycoplasma Testing for Targeted Therapy Development